See more : Hektas Ticaret T.A.S. (HEKTS.IS) Income Statement Analysis – Financial Results
Complete financial analysis of Olink Holding AB (publ) (OLK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Olink Holding AB (publ), a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Shaftesbury PLC (SHABF) Income Statement Analysis – Financial Results
- WebComm Technology Co., Ltd. (6865.TWO) Income Statement Analysis – Financial Results
- VoiceServe, Inc. (VSRV) Income Statement Analysis – Financial Results
- RKEC Projects Limited (RKEC.NS) Income Statement Analysis – Financial Results
- The Coretec Group Inc. (CRTG) Income Statement Analysis – Financial Results
Olink Holding AB (publ) (OLK)
About Olink Holding AB (publ)
Olink Holding AB (publ) provides various products and services for the academic, government, biopharmaceutical, biotechnology, and other institutions that focuses on life science research. Its products include Olink Explore for cardiovascular and metabolic, oncology, neurology, or inflammation diseases; Olink Target product line; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on. The company's products also comprise Olink Signature Q100, a qPCR readout platform; Olink Analysis services comprising study design and consultation, sample preparation and assay execution, and data processing and QC; and bioinformatics services. In addition, it provides Olink normalized protein expression (NPX) Manager, a purpose-built software that enable users to import data, validate data quality, and normalize for subsequent statistical analysis; and Olink Insight, a cloud platform for data visualization and statistical analysis of NPX data. Olink Holding AB (publ) sells its products and services through its own direct sales force in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Knilo HoldCo AB and changed its name to Olink Holding AB (publ) in January 2021. The company was founded in 2004 and is headquartered in Uppsala, Sweden. Olink Holding AB (publ) is a subsidiary of Summa Equity Holding AB.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 169.91M | 139.85M | 94.97M | 54.07M | 41.69M |
| Cost of Revenue | 71.04M | 45.35M | 36.76M | 17.46M | 13.02M |
| Gross Profit | 98.87M | 94.50M | 58.21M | 36.61M | 28.68M |
| Gross Profit Ratio | 58.19% | 67.57% | 61.29% | 67.71% | 68.78% |
| Research & Development | 30.57M | 26.35M | 22.14M | 9.63M | 4.85M |
| General & Administrative | 105.79M | 54.27M | 47.50M | 20.10M | 26.61M |
| Selling & Marketing | 12.24M | 44.67M | 33.67M | 12.72M | 8.25M |
| SG&A | 118.25M | 98.95M | 81.16M | 32.82M | 34.86M |
| Other Expenses | 0.00 | -191.00K | -443.00K | -475.00K | -363.00K |
| Operating Expenses | 148.81M | 125.10M | 102.86M | 41.98M | 39.34M |
| Cost & Expenses | 219.85M | 170.45M | 139.62M | 59.44M | 52.36M |
| Interest Income | 6.51M | 1.16M | 98.00K | 6.63M | 7.00K |
| Interest Expense | 858.00K | 531.00K | 2.05M | 6.63M | 6.60M |
| Depreciation & Amortization | 19.03M | 18.99M | 14.08M | 12.54M | 7.87M |
| EBITDA | -30.91M | -11.61M | -30.57M | 6.46M | -2.79M |
| EBITDA Ratio | -18.19% | -8.30% | -32.19% | 11.94% | -6.70% |
| Operating Income | -49.94M | -30.60M | -44.65M | -6.08M | -10.66M |
| Operating Income Ratio | -29.39% | -21.88% | -47.02% | -11.25% | -25.58% |
| Total Other Income/Expenses | 10.30M | 15.20M | -1.89M | -1.89M | -140.99K |
| Income Before Tax | -39.98M | -15.41M | -46.55M | -7.26M | -18.53M |
| Income Before Tax Ratio | -23.53% | -11.02% | -49.01% | -13.43% | -44.44% |
| Income Tax Expense | -8.32M | -2.56M | -8.21M | -479.00K | -652.00K |
| Net Income | -31.66M | -12.85M | -38.34M | -6.78M | -17.88M |
| Net Income Ratio | -18.63% | -9.19% | -40.37% | -12.54% | -42.88% |
| EPS | -0.26 | -0.11 | -0.39 | -0.03 | -0.07 |
| EPS Diluted | -0.26 | -0.11 | -0.39 | -0.03 | -0.07 |
| Weighted Avg Shares Out | 124.00M | 119.08M | 99.26M | 257.23M | 257.23M |
| Weighted Avg Shares Out (Dil) | 124.00M | 119.08M | 99.26M | 257.23M | 257.23M |
Thermo Fisher Scientific to Acquire Olink, a Leader in Next-Generation Proteomics
Landmark studies utilizing Olink® Explore technology signal a new era for population-scale proteogenomics
Announcing the Olink® Target 48 Mouse Cytokine Panel – the next generation in immunoassays designed to accelerate translational research.
Eurofins Genomics adopts Olink® technology to advance proteomics research and accelerate precision medicine programs
Olink to participate in September investor events
Olink Holding AB (publ) (OLK) Q2 2023 Earnings Call Transcript
Olink Holding AB (publ) Sponsored ADR (OLK) Reports Q2 Loss, Misses Revenue Estimates
Baylor College of Medicine Human Genome Sequencing Center adopts Olink® Explore HT proteomics platform
Wall Street Analysts Believe Olink Holding AB (publ) Sponsored ADR (OLK) Could Rally 31.22%: Here's is How to Trade
Olink to report second quarter 2023 financial results on August 9, 2023, and to participate in the Canaccord Genuity 43rd Annual Growth Conference
Source: https://incomestatements.info
Category: Stock Reports